Greenwich LifeSciences Expands FLAMINGO-01 Trial Scope with European Approval
Event summary
- European Medicines Agency (EMA) approved combining HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 trial, aligning with US protocol.
- All 170-180 clinical sites in the US and Europe now operate under the same protocol, potentially doubling enrollment rate.
- Non-HLA-A*02 patients, representing about 55% of the population, are now eligible for enrollment, reducing wait times up to a year.
- Preliminary data shows approximately 70-80% reduction in recurrence rates for non-HLA-A*02 patients after Primary Immunization Series (PIS).
- Company aims to pursue approval for both HLA-A*02 and non-HLA-A*02 patients using combined analysis, potentially doubling market for GP2.
The big picture
Greenwich LifeSciences' strategic shift to include both HLA populations in its pivotal trial addresses a significant unmet need, as non-HLA-A*02 patients represent over half of the potential market. This move aligns with broader industry trends towards personalized medicine and could set a precedent for future immunotherapy trials targeting diverse patient populations. The company's ability to streamline enrollment and potentially double its addressable market underscores the competitive advantage of its GP2 immunotherapy in preventing breast cancer recurrences.
What we're watching
- Regulatory Dynamics
- Whether UK and Canadian regulators will follow EMA's approval, allowing global harmonization of trial protocols.
- Market Expansion
- The pace at which Greenwich LifeSciences can accelerate clinical development for non-HLA-A*02 population, potentially doubling GP2's market.
- Clinical Efficacy
- How the combined analysis of HLA-A*02 and non-HLA-A*02 patient data will impact the statistical power and outcomes of FLAMINGO-01 trial.